Meet the MiSeq i100 Series – the new standard in sequencing simplicity with a 3-step setup, onboard DRAGEN analysis, and same-day results to accelerate genomic discovery and insights: https://bit.ly/4eTqugz
关于我们
At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
- 网站
-
http://www.illumina.com
Illumina的外部链接
- 所属行业
- 生物技术研究
- 规模
- 5,001-10,000 人
- 总部
- San Diego，CA
- 类型
- 上市公司
- 创立
- 1998
产品
![点击此处查看BaseSpace Clarity LIMS]()
BaseSpace Clarity LIMS
实验室信息管理系统 (LIMS)
BaseSpace Clarity LIMS is a laboratory information management system that helps genomics labs track samples and manage workflows for an optimized and efficient lab.
地点
Illumina员工
动态
-
Eric Kelsic and his team are driven by one thing: Accelerating drug discovery. Hear how Dyno Therapeutics is finding ways to keep people healthier, longer with the help of Illumina technology.
-
“These results further illustrate the paradigm shift in clinical practice in oncology. Patients are seeing better outcomes from precision treatments based on a tumor’s molecular profile compared to conventional approaches used to treat cancer.” – Swaroop Aradhya, VP of Medical and Clinical Affairs at Illumina. Powerful study of CGP, in partnership with Providence and Microsoft Research, published today in the Journal of Clinical Oncology. Congratulations to John Fox, Bela Bapat, Pratheesh Sathyan PhD and the many team members who contributed to this important work over several years.
We are excited to share the results of a novel joint study between Providence, Illumina and Microsoft Research, published today in the Journal of Clinical Oncology - Oncology Practice (JCO-OP). The study reveals that Comprehensive Genomic Profiling (CGP), when conducted early in a cancer patient’s diagnosis, leads to significantly better personalized treatment and patient outcomes. 🔬 Key Findings: ▶️ Early CGP testing resulted in over half of the patients receiving biomarker-driven targeted therapy or immunotherapy, significantly improving overall survival rates. ▶️ CGP test can identify actionable mutations based on either guideline-based treatment or clinical-trial matching for 67% of tumors, compared to only 33% of tumors with small-panel test 💡 Impact: ▶️ Early genomic testing empowers pathologists and oncologists to make informed clinical decisions, leading to better patient outcomes. These results underscore the urgency of integrating CGP into standard diagnostic practices to ensure patients receive the most effective treatments from the onset of their diagnosis. Learn more: http://ms.spr.ly/6041Wi0fc #CancerResearch #ComprehensiveGenomicProfiling #PrecisionMedicine #HealthcareInnovation #Providence #MicrosoftResearch #Illumina
-
-
How do some cancers become more aggressive than others? Luigi Mancinelli, PhD and his team at the University of Pittsburg are using the NovaSeq X Plus and Partek Flow to pinpoint gene activity that may drive osteosarcoma metastasis. By targeting these genetic markers, they hope to block the tumor’s ability to develop metastasis and bring new hope to patients. Learn more about their critical work: https://bit.ly/3Z4FW4k
-
-
That’s a wrap on #ASHG24. The conference was an incredible opportunity to connect with our customers and hear about the latest advancements in genomics (and beyond!). Together, we reviewed our innovation roadmap, shared preliminary data highlighting the impact of these developments, and introduced customers to the MiSeq i100 Series for the very first time. From constellation mapped read technology to proteomics, single cell, and bioinformatics, we continue to partner with our customers to build the solutions that meet their needs. For more on our latest developments and partnerships: https://lnkd.in/gpHz9GJg
-
-
-
-
-
+1
-
-
This Veteran’s Day marks the 4th year we have been recognized as a Best for Vets Employer by Military Times. We are honored to be included again, but we know the credit goes to our employees who create the inclusive workplace we strive for every day and to the veterans who choose to work at Illumina. A special thank you to all our U.S. veteran employees for their service and to the iSERVED employee resource group for fostering community through events like flag-raising ceremonies, volunteer activities, and career discussions.
-
-
Illumina转发了
It has been an inspiring few days spent at #ASHG24 with the Illumina team and so many of our customers and partners from across the #genomics industry. Especially pleased to hear all the positive feedback and excitement about our product pipeline, which includes a constellation map read technology, protein prep solution, and a new single-cell analysis solution from Fluent BioSciences Inc.. At Illumina, we are committed to making next generation sequencing (NGS) easier and more accessible, fueling our #mission to improve human health by unlocking the power of the genome. Thank you to ASHG CEO Amanda P. and her entire team for hosting such a great event.
-
-
Our recent acquisition of Fluent BioSciences is set to transform single-cell research. In our latest article, Cande Rogert and Soroush Zarandi, PhD, MBA discuss how PIPseq V simplifies workflows and brings high-throughput applications to every lab. Dive into the details and see how we’re making cutting-edge technology accessible to all: https://bit.ly/4f8rBcL. And if you’re attending #ASHG24, don’t miss our talk on the power of PIPseq V in scRNA-Seq!
-
-
For IT Director Suresh Gadamsetti, Diwali this year is extra special. It’s the first time in nearly two decades he’ll celebrate the festival of lights back in India, surrounded by family and his community. Learn more about Suresh’s journey back to India and what #Diwali means to him: https://bit.ly/4fovauV #IlluminaProud
-